BCM
CTNM

Boxer Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Boxer Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.1M Hold
494,000
– – 0.61% 32
2026
Q1 		$6.45M Hold
494,000
– – 0.85% 30
2025
Q4 		$5.65M Buy
+494,000
New +$5.64M 1.24% 24

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boxer Capital Management's CTNM Position: Q2 2026 in Review

Boxer Capital Management held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 494,000 shares worth $8.1M. The position accounts for 0.61% of the portfolio, ranked #32.

Boxer Capital Management first reported a position in CTNM in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Boxer Capital Management held 494,000 shares of Contineum Therapeutics worth $8.1M as of Q2 2026.
  • Boxer Capital Management left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up 0.61% of Boxer Capital Management's portfolio in Q2 2026, its #32 holding.
  • Boxer Capital Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.